Intervention

olanzapine

ClinicalTrials.gov intervention label

Clinical trials42

Recruiting3

Common conditions25

Lead sponsors shown15

Clinical trials

42 shown

Olanzapine Based Dexamethasone-sparing Regimen for Breast Cancer Patients With Metabolic-risk FactorsNCT07743827 · 2026-05-10

Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic MedicationsNCT07565428 · 2026-04-23

Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia PatientsNCT05669742 · 2023-05-25

A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic MedicationNCT03557931 · 2018-07-13

5-HTR2A, DRD2,and COMT Genes Polymorphisms and Olanzapine Plasma Concentration in Treatment of Early-onset SchizophreniaNCT02435654 · 2015-08-01

Integrating Psychotropic Medication Into the Care of People With Mental Disorders in a Prayer Camp in GhanaNCT02593734 · 2013-07-01

Antipsychotic to Treat Psychosis SyndromeNCT02137616 · 2012-06-01

A Follow up Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective DisorderNCT01389908 · 2011-06-01

A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of SchizophreniaNCT01234779 · 2011-02-01

Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric HospitalNCT01193166 · 2010-08-01

Antipsychotics and Gene Expression in Soft TissuesNCT01185743 · 2010-07-01

15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and IncarceratedNCT01157351 · 2010-05-01

Interaction Between Fosamprenavir/Ritonavir and a Single-dose Olanzapine (FORZA)NCT00977301 · 2009-11-01

Polypharmacy in Clozapine-resistant SchizophreniaNCT00918021 · 2009-06-01

A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic PatientsNCT00845026 · 2009-03-01

Standard Comprehensive Intervention to Treat First-episode SchizophreniaNCT01057849 · 2008-09-01

A Study of Zonisamide to Prevent Olanzapine-Associated Weight GainNCT00363376 · 2008-01-01

A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With SchizophreniaNCT00645099 · 2007-10-01

An Observational Study of Olanzapine Coated and Orodispersible Tablets Effectiveness in Schizophrenic and Bipolar Outpatients.NCT00510211 · 2007-04-01

Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With OlanzapineNCT00401973 · 2006-11-01

Efficacy Study of Early Onset of Antipsychotic Drug Action in SchizophreniaNCT00337662 · 2006-05-01

Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With SchizophreniaNCT00320489 · 2006-04-01

6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patients Who Completed the Protocol 25543 (25544)(P05777)NCT00265343 · 2005-12-01

Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and PlaceboNCT00149292 · 2005-08-23

6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772)NCT00174265 · 2005-07-01

Efficacy and Safety of Asenapine With Placebo and Olanzapine (41021)(P05933)NCT00156117 · 2005-05-12

Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (25543)(COMPLETED)(P05817)NCT00212836 · 2005-04-21

Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25520)(P05846)NCT00212771 · 2004-09-01

Energy Homeostasis Under Treatment With Atypical AntipsychoticsNCT00148564 · 2004-03-01

Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid MetabolismNCT00287820 · 2004-02-01

Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective DisorderNCT00190749 · 2003-10-01

Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)NCT00212784 · 2003-09-04

A Comparison of Two Standard Therapies in the Management of Dementia With AgitationNCT00208819 · 2003-09-01

Efficacy Study of Switching Stabilized Schizophrenic Patients From Conventional to Atypical Antipsychotic TreatmentNCT00191555 · 2003-08-01

Kahn Study; Investigation Of The Efficacy Of Ziprasidone Versus Olanzapine In The Management Of Recent-Onset Psychosis; A Flexible-Dose, Parallel Group, Double-Blind StudyNCT00145444 · 2003-03-01

A Comparative Study of New Medications for Psychosis in AdolescentsNCT00222495 · 2002-08-01

Glucose and Lipid Metabolism on Antipsychotic MedicationNCT00515723 · 2001-09-01

Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With SchizophreniaNCT00034801 · 2001-09-01

CATIE- Schizophrenia TrialNCT00014001 · 2000-12-01

Glucose Regulation During Risperidone and Olanzapine TreatmentNCT00006195

A Combination of Two Currently Approved Drugs to Enhance the Treatment of SchizophreniaNCT00089869

Effectiveness of Atypical Versus Conventional Antipsychotics in Treating SchizophreniaNCT00237861

Common conditions

Leading sponsors

Eli Lilly and Company8 Organon and Co6 Denovo Biopharma LLC2 Alexandria University1 Astellas Pharma Global Development, Inc.1 Central South University1 Charite University, Berlin, Germany1 Emory University1 Hoffmann-La Roche1 Janssen Scientific Affairs, LLC1 Janssen-Cilag International NV1 Kunming Medical University1 Lindner Center of HOPE1 Medical University of Vienna1 Minerva Neurosciences1

Trial status mix

COMPLETED34

UNKNOWN4

RECRUITING3

WITHDRAWN1

Phase mix

PHASE415

PHASE313

NA7

PHASE25

PHASE12

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.